AURX · Nuo Therapeutics, Inc.
$1.24
-0.02 (-1.58%)
At close · Sep 17
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We believe based on the operating cash requirements and capital expenditures expected for the next twelve months that our current resources and projected revenue from sales of Aurix products and the Private Label product to Smith+Nephew are insufficient to support our operations for the next 12 months from the date these financial statements are issued. As such, we believe that substantial doubt about our ability to continue as a going concern exists.”View the 10-Q filed Aug 14, 2026
Market Cap
$61.03M
Shares
48.43M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.24
Open$1.27
Day$1.20–1.27
52W close$0.77–3.23
Avg vol 30d6K
Short int3K · 0.0% float · 1.0d
Short vol12%
DataJan 2020–Sep 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$5.20M
Trailing 12 months
Net income (TTM)
−$2.01M
Trailing 12 months
Revenue growth YoY
+152.6%
Year over year
Operating margin
-33.3%
Trailing 12 months
P / E (TTM)
4.7
Trailing earnings · reciprocal yield 21.4%
FCF yield
-4.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+24.8%
Year over year · more shares
Price change (1Y)
-31.5%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
+19%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
19%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+46%
trailing
6-month return
−37%
trailing
YTD return
−37%
this year
Relative strength
−55%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$9.5K over 90 days · 0% sells
Short interest
Rising
0.01% of float · ▲ +204.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
44
elevated · 0–100
Fundamentals
Revenue growth
−94%
Y/Y
Gross margin
308%
expanding
EPS growth
−111%
Y/Y
Free cash flow
$-1.1M
Balance sheet
$693.5K
net cash
Quant / Vol
risk profile
Volatility
111%
annualized · 1-yr
Max drawdown
−76%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
+19%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
19%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$9.5K over 90 days · 0% sells
Short interest
Rising
0.01% of float · ▲ +204.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $1
Now $1 · 19%
Range high $3
vs 200-day avg -23%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AURX
this stock
Nuo Therapeutics, Inc.
|
$61.03M | -37.1% | +142.7% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.06B | +13.9% | +46.2% | 29.9 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.83B | +2.3% | +20.8% | 19.2 | 2.5% |
|
ARGX
Argenx SE
|
$60.93B | +18.4% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$59.64B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Smart Money
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AURX | +0.8% | +45.9% | -37.1% | +8.8% | -37.1% |
| SPY | +0.6% | -0.8% | +18.2% | -0.6% | +11.8% |
| vs SPY | +0.2% | +46.7% | -55.3% | +9.4% | -48.9% |